Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tavipec in acute rhinosinusitis
2013-002977-23Phase 4Completed
- Sponsor
- Montavit
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in acute rhinosinusitis (ARS) comparing Tavipec with Placebo (2 arms). Primary endpoint: Major Symptom Score difference after 4 days. Started Nov 2013; status: completed.
02
Drugs
Tavipec
03
Conditions
acute rhinosinusitis (ARS)
Beyond the preview
Go deeper on 2013-002977-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002977-23.